ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, OR BIPOLAR DISORDER

Author(s)

Jeff Jianfei Guo, PhD, Associate Professor1, Nick C. Patel, Pharm, PhD, Assistant Professor2, Yonghua Jing, MS, Research Assistant1, Christina ML. Kelton, PhD, Professor1, Huihao Fan, MSc, Senior Statistician3, Paul Keck, E, Professor11University of Cincinnati, Cincinnati, OH, USA; 2 University of Georgia, Augusta, GA, USA; 3 Covance Inc, Sun Prairie, WI, USA

OBJECTIVES: Patients with schizophrenia, schizoaffective disorder, or bipolar disorder often receive multiple medications as part of their treatment regimens.  Since many antipsychotics are metabolized by cytochrome P450 (CYP450) isoenzymes (1A2, 2D6, and 3A4), we proposed to assess the risk of receiving potential drug-drug interaction (DDI) pairs associated with the inhibition or induction of CYP450 isoenzymes.  METHODS: Using the Ohio fee-for-service Medicaid claims database from January 1, 2001 to December 31, 2003, a total of 44,511 patients (18≤age≤65) with a schizophrenia, schizoaffective disorder, or bipolar disorder diagnosis and receiving at least one study antipsychotic were selected for this study. Study antipsychotics included chlorpromazine, haloperidol, perphenazine, aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone. Any clinically significant (moderate or severe) DDI pair was defined to have concomitant exposure if 1) an antipsychotic and an interacting medication were dispensed on the same day, or 2) any of the days supply for an antipsychotic prescription overlapped with the days supply of an interacting medication by at least one day. Three sub-cohorts, patients with schizophrenia, schizoaffective disorder, and bipolar disorder, were analyzed separately. Multivariable logistic regression analysis was used to assess risk factors associated with the receipt of a potential DDI pair. RESULTS: Of the 44,511 study patients, potential DDI pairs were received by 12.1% (11.9% in schizophrenia, 12.9% in schizoaffective, and 11.8% in bipolar sub-cohorts) as same-day prescriptions dispensed and by 24.5% (24.7% in schizophrenia, 26.5% in schizoaffective, and 24.5% in bipolar sub-cohorts) as prescriptions with at least a one-day overlap.  The most frequent DDI pairs were observed with olanzapine (45.0%), risperidone (23.5%), and quetiapine (13.4%).  A higher risk of receiving a potential DDI pair was associated with being white (odds ratio [OR]=1.27, 95% confidence interval [CI]: 1.21-1.34), treatment duration over 12 months (OR=1.13, 95% CI: 1.07-1.19), age older than 45 (OR=1.11, 95% CI: 1.06-1.17), depression (OR=1.20, 95% CI: 1.14-1.27), impulse control disorder (OR=1.53, 95% CI: 1.30-1.79), and several major medical comorbidities like diabetes mellitus (OR=1.12, 95% CI: 1.05-1.20), cerebrovascular disease (OR=1.34, 95% CI: 1.13-1.59).  CONCLUSIONS: The potential drug-drug interactions should be considered when treating patients with some antipsychotics, especially during the long-term maintenance use. Patients with key psychiatric and medical comorbidities had a higher risk of receiving potential DDI pairs.

Conference/Value in Health Info

2008-09, ISPOR Asia Pacific 2008, Seoul, South Korea

Value in Health, Vol. 11, No. 6 (November 2008)

Code

PMH15

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×